Portland, ME19 Active Studies

Pulmonary Hypertension Clinical Trials in Portland, ME

Find 19 actively recruiting pulmonary hypertension clinical trials in Portland, ME. Connect with local research sites and explore new treatment options.

19
Active Trials
17
Sponsors
2,556
Enrolling

Recruiting Pulmonary Hypertension Studies in Portland

RecruitingPortland, MENCT05947851

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypothese...

720 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingPortland, MENCT06233799

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing...

360 participants
National Institute on Drug Abuse (NIDA)
View Study Details
RecruitingPortland, MENCT06564038

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies....

276 participants
AstraZeneca
View Study Details
RecruitingPortland, MENCT05948943

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as ...

232 participants
Novartis Pharmaceuticals
View Study Details
RecruitingPortland, MENCT05289661

Descemet Endothelial Thickness Comparison Trial I

Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose...

160 participants
Stanford University
View Study Details
RecruitingPortland, MENCT06581198

A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus ...

144 participants
Novartis Pharmaceuticals
View Study Details
RecruitingPortland, MENCT05721222

Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers. Part...

110 participants
Genmab
View Study Details
RecruitingPortland, MENCT05169060

Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy

Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes, affecting about 50% of patients with diabetes and leading to severe morbidity, poor quality of life, high mort...

100 participants
University of Iowa
View Study Details
RecruitingPortland, MENCT05563766

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a...

78 participants
VA Office of Research and Development
View Study Details
RecruitingPortland, MENCT05693142

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is...

65 participants
REGENXBIO Inc.
View Study Details
RecruitingPortland, MENCT05275972

Descemet Endothelial Thickness Comparison Trial II

Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DM...

60 participants
Stanford University
View Study Details
RecruitingPortland, MENCT06534060

MB-105 in Patients With CD5 Positive T-cell Lymphoma

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon tw...

46 participants
March Biosciences Inc
View Study Details
RecruitingPortland, MENCT05654506

Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin...

40 participants
Mayo Clinic
View Study Details
RecruitingPortland, MENCT05871970

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the...

38 participants
Protara Therapeutics
View Study Details
RecruitingPortland, MENCT05836259

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyop...

30 participants
Tenaya Therapeutics
View Study Details
RecruitingPortland, MENCT06164587

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macula...

30 participants
University of Kentucky
View Study Details
RecruitingPortland, MENCT05787639

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

The majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. However, targeting tumors with stereotactic radiation in combination with...

29 participants
University of California, San Diego
View Study Details
RecruitingPortland, MENCT06175000

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer ...

28 participants
Providence Health & Services
View Study Details
RecruitingPortland, MENCT03801434

Ruxolitinib in Treating Patients with Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders....

10 participants
William Shomali
View Study Details

About Pulmonary Hypertension Clinical Trials in Portland

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 19 pulmonary hypertension clinical trials recruiting participants in Portland, ME. These studies are seeking a combined 2,556 participants. Research is being sponsored by Merck Sharp & Dohme LLC, National Institute on Drug Abuse (NIDA), AstraZeneca and 14 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Portland — FAQ

Are there pulmonary hypertension clinical trials in Portland?

Yes, there are 19 pulmonary hypertension clinical trials currently recruiting in Portland, ME. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Portland?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Portland research site will contact you about next steps.

Are clinical trials in Portland free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Portland studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 19 active trials in Portland are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated March 2, 2026 from ClinicalTrials.gov